No Data
GenScript Biotech (01548): CARVYKTI generated net trade sales of approximately USD 597 million for the quarter ended March 31, 2026.
Genscript Biotech (01548) announced that, according to the collaboration and license agreement dated December 21, 2017, between Legend Biotech Corporation (an associated company of Genscript Biotech, whose shares are listed on the Nasdaq Global Select Market in the form of American Depositary Shares) and Janssen Biotech, Inc. (Janssen), CARVYKTI generated net trade sales of approximately USD 597 million for the quarter ended March 31, 2026.
J&J Raises 2026 Outlook as Oncology Products Power Q1 Beat
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $62
RBC Capital Sticks to Their Buy Rating for Legend Biotech (LEGN)
Healthcare Quant Check: RLAY and TNGX Lead Seeking Alpha's Top Picks Ahead of Q1 Earnings
Legend Biotech Earnings Call Highlights CARVYKTI Momentum